Diabetic Foot Ulcer Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
DIABETIC FOOT ULCER THERAPEUTICS PIPELINE ANALYSIS
• Diabetes mellitus is a metabolic disorder which is one of the most important public health concerns worldwide, leading to an increased risk of causing diabetic foot ulcer. As per studies, one-fourth of the diabetes patients are going to face the risk of foot ulcer development during a lifetime.
• Diabetic foot ulcers are sores that occur on the feet of diabetic people. Symptoms include ulcers, or blisters on the foot or lower leg, sores associated with pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, or skin redness, swelling, or other signs of infection.
• The predisposing factors such as diabetic neuropathy, a foot deformity, peripheral vascular disease and history of tobacco use disorder.
• Foot ulcers develop due to the composite interaction between three entities, like ischemia, neuropathy, and infection. Wound healing is going to occur in four phases, like hemostasis, inflammatory, proliferative, and maturation.
• The wound healing therapeutics is one of the major trends that are being witnessed in the diabetic foot ulcers market. SER190 developed by Serodus is in the pre-clinical stage of development for the diabetic ulcers treatment.
• Thus, a number of clinical trials are being conducted wherein a large number of organizations are participating actively in extended research programs for developing novel therapies.
• Over the last few decades, they have been focusing on introducing breakthrough advanced wound dressings for the management of diabetic foot ulcer.
• This includes novel dressings with the ability to confer moisture balance with prolonged time of action, extended oxygen permeability, antimicrobial activity, growth factor stimulation, and the ability to promote autolytic debridement thus facilitating the re-epithelialization process.
• Several promising therapeutic agents are developed, which are expected to increase the growth of the diabetic foot ulcers market. The number of clinical trials is increasing at a rapid rate.
• A phase III trial of BioChaperone is initiated by Virchow Group and Adocia to evaluate the efficiency and safety of the dose regimens of BioChaperone PDGF-BB to Becaplermin Gel for the disease treatment.” The DFU therapeutics market is made up of the diabetic foot infection (DFI) and wound healing sectors.
• The wound healing therapeutics market has just one product – Regranex which was slapped a ‘black box’ warning by USFDA due to concerns that large quantities could increase the risk of cancer. The three major drugs in DFI area all have side effect issues: Zyvox, Invanz, and Zosyn. The DFU therapeutics pipeline constitutes 40 molecules, 29 of which can swank the first-in-class status.
• In the wound-healing sector, the controversial Regranex was expected to replace by treatments such as Fragmin, CVBT141B and Trafermin. In contrast, patent expiration of Zyvox and Invanz can affect the DFI sector. This will propel generic alternatives.
• The strong drug development pipeline, growing population, affected by diabetes and increase in the number of people with diabetic foot ulcer is likely to drive the global diabetic foot ulcer therapeutics market in a positive manner over the next decade.
• Furthermore, continued prioritization to avoid surgeries and amputations is expected to fuel the global diabetic foot ulcer therapeutics market growth over the predicted period. The trends affecting this market are the increasing wound healing therapeutics, Growing number of strategic alliances, Increase in R&D activities.
• One of the major challenges of the global diabetic foot ulcers therapeutics market is the high rate of product discontinuation and the low number of approved drugs for the diabetic foot ulcers treatment.
• Diabetes mellitus is a metabolic disorder which is one of the most important public health concerns worldwide, leading to an increased risk of causing diabetic foot ulcer. As per studies, one-fourth of the diabetes patients are going to face the risk of foot ulcer development during a lifetime.
• Diabetic foot ulcers are sores that occur on the feet of diabetic people. Symptoms include ulcers, or blisters on the foot or lower leg, sores associated with pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, or skin redness, swelling, or other signs of infection.
• The predisposing factors such as diabetic neuropathy, a foot deformity, peripheral vascular disease and history of tobacco use disorder.
• Foot ulcers develop due to the composite interaction between three entities, like ischemia, neuropathy, and infection. Wound healing is going to occur in four phases, like hemostasis, inflammatory, proliferative, and maturation.
• The wound healing therapeutics is one of the major trends that are being witnessed in the diabetic foot ulcers market. SER190 developed by Serodus is in the pre-clinical stage of development for the diabetic ulcers treatment.
• Thus, a number of clinical trials are being conducted wherein a large number of organizations are participating actively in extended research programs for developing novel therapies.
• Over the last few decades, they have been focusing on introducing breakthrough advanced wound dressings for the management of diabetic foot ulcer.
• This includes novel dressings with the ability to confer moisture balance with prolonged time of action, extended oxygen permeability, antimicrobial activity, growth factor stimulation, and the ability to promote autolytic debridement thus facilitating the re-epithelialization process.
• Several promising therapeutic agents are developed, which are expected to increase the growth of the diabetic foot ulcers market. The number of clinical trials is increasing at a rapid rate.
• A phase III trial of BioChaperone is initiated by Virchow Group and Adocia to evaluate the efficiency and safety of the dose regimens of BioChaperone PDGF-BB to Becaplermin Gel for the disease treatment.” The DFU therapeutics market is made up of the diabetic foot infection (DFI) and wound healing sectors.
• The wound healing therapeutics market has just one product – Regranex which was slapped a ‘black box’ warning by USFDA due to concerns that large quantities could increase the risk of cancer. The three major drugs in DFI area all have side effect issues: Zyvox, Invanz, and Zosyn. The DFU therapeutics pipeline constitutes 40 molecules, 29 of which can swank the first-in-class status.
• In the wound-healing sector, the controversial Regranex was expected to replace by treatments such as Fragmin, CVBT141B and Trafermin. In contrast, patent expiration of Zyvox and Invanz can affect the DFI sector. This will propel generic alternatives.
• The strong drug development pipeline, growing population, affected by diabetes and increase in the number of people with diabetic foot ulcer is likely to drive the global diabetic foot ulcer therapeutics market in a positive manner over the next decade.
• Furthermore, continued prioritization to avoid surgeries and amputations is expected to fuel the global diabetic foot ulcer therapeutics market growth over the predicted period. The trends affecting this market are the increasing wound healing therapeutics, Growing number of strategic alliances, Increase in R&D activities.
• One of the major challenges of the global diabetic foot ulcers therapeutics market is the high rate of product discontinuation and the low number of approved drugs for the diabetic foot ulcers treatment.
